Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM...
June 27 2019 - 7:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced multiple
presentations of its innovative programs including
sulbactam-durlobactam (ETX2514SUL), zoliflodacin and ETX0282CPDP,
during the American Society for Microbiology (ASM) Microbe
Conference 2019. Durlobactam has been approved as the international
nonproprietary name for ETX2514.
Manos Perros, President and Chief Executive
Officer of Entasis Therapeutics, commented, “The consequential
scientific findings presented on the podium and during poster
presentations at ASM Microbe this year illustrate the continued
advancement of our unique pathogen-targeted antimicrobial programs.
In particular, the results presented confirm the potent
antibacterial activity of our clinical drug candidates and
highlight promising data from our preclinical discovery platform. I
am proud of the complex, exacting work our organization is
undertaking every day in battling the toughest superbugs. What we
do matters—to clinicians and the patients they serve.”
During the conference, Ruben Tommasi, PhD, Chief
Scientific Officer at Entasis, provided an overview of the
Company’s pipeline, underscoring the broad antibacterial activity
of sulbactam-durlobactam against Acinetobacter through inhibition
of Class A, C and D β-lactamases and the potential utility of
zoliflodacin as a novel single-dose oral treatment for gonorrhea.
Dr. Tommasi also discussed ETX0282CPDP’s potential as a
best-in-class oral agent with potent microbiological activity
against multi-drug resistant Enterobacteriaceae, and the Company’s
novel non-beta-lactam PBP inhibitor (NBP) program designed to
address serious Gram-negative infections.
John O’Donnell, Senior Director of Drug
Metabolism and Pharmacokinetics at Entasis, spoke and provided a
poster presentation on pharmacokinetics, pharmacodynamics and dose
projections for sulbactam-durlobactam. These results formed the
basis of the dosing regimen tested in the Phase 2 and ongoing
ATTACK Phase 3 clinical trial.
John Mueller, PhD, Chief Development Officer of
Entasis, reviewed novel therapies targeting drug-resistant
gonorrhea, including Entasis’ first-in-class antibiotic
zoliflodacin, which represents the only known novel treatment in
late-stage development against this pathogen.
In addition, multiple poster presentations
demonstrated the potent antibacterial activity of
sulbactam-durlobactam against recent geographically diverse,
multidrug-resistant Acinetobacter isolates, and the potent
antibacterial activity of ETX0282CPDP against contemporary
multidrug-resistant Enterobacteriaceae isolates.
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ pathogen-targeted design platform
has produced a pipeline of product candidates, including
sulbactam-durlobactam (targeting Acinetobacter
baumannii infections), zoliflodacin (targeting Neisseria
gonorrhoeae), and ETX0282CPDP
(targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information,
visit www.entasistx.com.
Entasis Company Contact Kyle
Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations ContactTram BuiThe Ruth
Group(646) 536-7035tbui@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Apr 2024 to May 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From May 2023 to May 2024